% | $
Quotes you view appear here for quick access.

Regeneron Pharmaceuticals, Inc. Message Board

  • stockexpertpro stockexpertpro Nov 29, 2012 9:44 AM Flag

    TZYM Biotech trading way under cash with a blockbuster drug Way Oversold MultiBagger Potential


    TZYM Multi Bagger Potential Biotech trading way under cash with a blockbuster drug in the pipeline stock is currently extremly over sold and way undervalued

    Sentiment: Strong Buy

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Nice try......Trying some other board to pump this dog stock!!!!

      Shares of Tranzyme Inc. slumped to new lows Friday, a day after the company said its diabetic gastroparesis drug TZP-102 failed in a clinical trial.

      THE SPARK: On Thursday, Tranzyme said once-per-day doses of TZP-102 did not work better than a placebo at treating the condition. Gastroparesis is a condition in which the stomach takes too long to clear out food. Tranzyme said it affects about 12 percent of people with diabetes, and causes nausea, vomiting, dehydration, and difficulty digesting food.

      THE BIG PICTURE: TZP-102 is Tranzyme's most advanced drug candidate, and the company is conducting a separate trial where patients take the drug three times per day instead of one. However this is the second time in 2012 that the company's top experimental drug has failed in clinical testing. In March, Tranzyme said it was stopping research on a drug called ulimorelin.

372.13-5.60(-1.48%)2:57 PMEDT